[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634163":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":23,"responsibleParty":39,"collaborators":10,"id":41,"slug":10,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":10,"enrollmentInfo":50,"targetDuration":10,"studyType":53,"phases":10,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Niguarda Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"mCRC patients",null,"Patients diagnosed with mCRC and screened by ctDNA within the MEN1611-02 clinical trial.",[13],{"name":14,"affiliation":15,"role":16},"Salvatore Siena, MD","ASST Niguarda Hospital","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":21,"email":22},"CONTACT","+39026444","3695","salvatore.siena@ospedaleniguarda.it",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"ASST GOM Niguarda","RECRUITING","Milan","Italia","Italy","IT",{"type":32,"coordinates":33},"Point",[34,35],12.59836,42.78235,{"lat":35,"lon":34},[38],{"name":14,"role":19,"phone":20,"phoneExt":21,"email":22},{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100634163",false,"NCT07536113","Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)","Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort","RealCHALLENGE","Inclusion criteria\n\n1. Patients diagnosed with MSS RAS and BRAF wild-type (on solid tissue) mCRC and screened by ctDNA within the MEN1611-02 clinical trial;\n2. Informed consent signature from alive patient;\n3. Availability of clinical data detailing the outcome to the first treatment received by patients following the blood draw for ctDNA analysis performed as per screening procedures within the MEN1611-02 clinical trial;\n4. Signed informed consent for molecular screening within the MEN1611-02 clinical trial.\n5. Age ≥ 18.\n\nExclusion criteria\n\n1. No data available detailing the outcome to the first treatment received by patients following the blood draw for ctDNA analysis performed as per screening procedures within the MEN1611-02 clinical trial.\n2. Patients enrolled and treated within the MEN1611-02 clinical trial.","ALL","18 Years",{"count":51,"type":52},250,"ESTIMATED","OBSERVATIONAL","This is an observational, retrospective, international and multicenter study funded by Fondazione Oncologia Niguarda ETS to assess the efficacy of anti-EGFR rechallenge regimens in the largest real-world cohort of MSS mCRC patients screened for RAS\u002FBRAF\u002FPIK3CA ctDNA status on liquid biopsy within the MEN1611-02 C-PRECISE-01 trial. The study will collect molecular, clinical and outcome data of patients already available at participating centers.",[56],"Metastatic Colorectal Cancer (CRC)",[58,59,60,61],"liquid biopsy","mCRC","rechallenge therapies","Anti-EGFR","2026-04-15",{"date":64,"type":65},"2026-04-17","ACTUAL",{"date":67,"type":65},"2024-03-01",{"date":69,"type":52},"2026-09-01",{"name":5,"class":6},1]